MarketCap
Facebook
X
TelegramAnnual report 2023
added 04-16-2024
Advaxis EBITDA 2011-2026 | ADXS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Advaxis
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.9 M | -37.3 M | -18.4 M | -24.5 M | -16.5 M | -68.9 M | -97.4 M | -76 M | -48.4 M | -19.3 M | -14.5 M | -12.2 M | -12.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.2 M | -97.4 M | -37.1 M |
Quarterly EBITDA Advaxis
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -11.8 M | -4.15 M | -10.1 M | -7.85 M | -9.82 M | -3.77 M | - | -4.08 M | -6.2 M | -7.66 M | -19.4 M | -5.64 M | -6.12 M | 10.6 M | -6.84 M | -9.83 M | -7.57 M | -20.3 M | -47.4 M | -13.9 M | -13.3 M | -17 M | -70 M | -32.5 M | -20.5 M | -19.9 M | -51.9 M | -16.5 M | -15.5 M | -6.77 M | -34.2 M | -13.6 M | -13.8 M | -5.92 M | -14.5 M | -5.95 M | -2.55 M | -2.14 M | -10.6 M | -3.01 M | -5.44 M | -3.21 M | -9.95 M | -3.55 M | -3.19 M | -2.94 M | -9.88 M | -3.56 M | -3.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 M | -70 M | -12.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.38 | -1.08 % | $ 367 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
-144 M | $ 20.52 | 0.79 % | $ 2.86 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.72 | 3.24 % | $ 8.95 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 2.57 | -3.48 % | $ 16.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Forte Biosciences
FBRX
|
-70.6 M | $ 26.92 | 1.8 % | $ 349 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.22 | -3.12 % | $ 178 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-83.4 M | $ 7.72 | -1.4 % | $ 489 K | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.24 | -12.55 % | $ 143 M | USA |
 |
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Gilead Sciences
GILD
|
10.4 B | $ 138.79 | -0.96 % | $ 173 B | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
42 K | $ 0.56 | 8.45 % | $ 521 K |  Israel |
 |
Genmab A/S
GMAB
|
6.57 B | $ 27.26 | -1.77 % | $ 17.2 B |  Danmark |
 |
Gossamer Bio
GOSS
|
-171 M | $ 0.32 | -7.03 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.02 | -2.55 % | $ 6.83 B |  Spain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.41 | -7.26 % | $ 2.26 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
15.3 B | $ 88.74 | -2.78 % | $ 27.2 B | Germany |
 |
Halozyme Therapeutics
HALO
|
480 M | $ 63.49 | 0.64 % | $ 7.61 B | USA |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.62 | -3.1 % | $ 190 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 3.32 | -6.21 % | $ 224 B | Britain |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 318.56 | -3.57 % | $ 41.7 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
232 M | $ 27.62 | -0.34 % | $ 1.59 B | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
iBio
IBIO
|
-18.1 M | $ 2.08 | 2.47 % | $ 21.8 M | USA |
 |
ImmuCell Corporation
ICCC
|
4.43 M | $ 6.54 | -1.06 % | $ 59 M | USA |
 |
InflaRx N.V.
IFRX
|
-37.3 M | $ 0.99 | 4.91 % | $ 152 M | Germany |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.46 | -0.45 % | $ 729 M | Britain |
 |
Immutep Limited
IMMP
|
-8.4 M | $ 0.35 | -3.58 % | $ 1.08 B | Australia |